Lexaria Bioscience Corp. | Income Statement
Fiscal year is September-August. All values USD Thousands.
2012
2013
2015
2016
2017
2018
Sales/Revenue
1,357.80
1,097.50
14.70
40.70
63.60
433.30
Cost of Goods Sold (COGS) incl. D&A
783.30
795.20
29.90
46.20
31.20
27.50
Gross Income
574.50
302.30
15.20
5.50
32.40
405.80
SG&A Expense
558.90
353.10
1,909.50
1,206.10
1,896.00
7,006
EBIT
13.90
56.90
1,928.20
1,259.60
1,929.90
6,613.20
Unusual Expense
-
19.30
22.70
-
-
-
Non Operating Income/Expense
-
-
-
-
6.40
4
Interest Expense
237.60
267.40
32.40
17.60
6.00
-
Pretax Income
251.50
343.60
1,983.30
1,277.20
1,929.50
6,609.20
Consolidated Net Income
251.50
343.60
1,983.30
1,277.20
1,929.50
6,609.20
Net Income
251.50
343.60
1,819.40
1,214.80
1,869.30
6,598.80
Net Income After Extraordinaries
251.50
343.60
1,868.30
1,214.80
1,869.30
6,598.80
Net Income Available to Common
251.50
343.60
1,770.50
1,214.80
1,869.30
6,598.80
EPS (Basic)
0.01
0.02
0.05
0.03
0.03
0.09
Basic Shares Outstanding
18,074.60
18,074.60
39,700.80
43,840.40
58,765.80
70,960.40
EPS (Diluted)
0.01
0.02
0.04
0.03
0.03
0.09
Diluted Shares Outstanding
18,074.60
18,074.60
39,700.80
43,840.40
58,765.80
70,960.40
EBITDA
442.70
286.20
1,928.20
1,259.00
1,928.40
6,610.90
Other Operating Expense
29.50
6.10
3.60
48.00
66.20
13
Minority Interest Expense
-
-
163.90
62.50
60.20
10.30
About Lexaria Bioscience
View Profile
